Concern Grows Over Alzheimer’s Drug

Aduhelm, Biogen’s controversial new Alzheimer’s drug, is facing more scrutiny after a JAMA Neurology article released yesterday found that 41% of trial participants who got a high dose of the drug experienced brain bleeding or swelling. 

The study was released as news broke that a 75-year-old clinical trial participant who had received infusions of Aduhelm died after experiencing brain swelling—though the link to the drug has not been proven, The New York Times reports.  

While most of those who experienced brain swelling during the study were asymptomatic, researchers are still trying to understand the implications of the side effects now that the drug is on the market.

Back story: The FDA approved the drug this summer, despite an independent advisory committee’s vote to reject the drug, Bloomberg reports.

Secondary Topic
Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top